Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Comment by overthelakeonlyon Sep 08, 2016 1:15pm

121 Views

Post# 25218571

RE:RE:Rodman & Renshaw conference

If untreated patients with EAA>0.60 and MODS >9, not randomized (for any reason) had a mortality rate of +60%, we can suppose that there is, at least, 54% of randomized patients with placebo died. Then, to obtain 92 (46X2), we have 38% mortality rate with PMX.-------------------------------------------------------It is the same thing up to 60-32%.---------------------------------------------------But I think that the magic number is 56-36% (92) for 20% absolute.

Bullboard Posts

Crypto and blockchain stock ends year with a profit